Europe rejects Wisconsin's key stem-cell patent
Human embryonic stem cells whose derivation requires the destruction of embryos cannot be patented, the appeals board of the European Patent Office (EPO) ruled on 27 November (see also 'Europe to pay royalties for cancer gene' , page 556).
The decision concludes a 13-year battle over a patent application from the Wisconsin Alumni Research Foundation for a method to derive stem cells from the undifferentiated cells of human embryos. The patent, which has been granted by the US Patent and Trademark Office, would also have covered some of the most commonly used human embryonic stem-cell lines.
The EPO decided that the patent contravenes a clause in its own convention, which says that anything whose exploitation is considered "contrary to public order or morality" cannot be patented. The ruling will not affect patents or patent applications on adult stem cells. 
Hawking plans long commute to Canada

Chemicals firm cancels plans for biodiesel plant
The world's third-largest chemicals company, Ineos, has shelved plans to build four large European biodiesel plants because of the "continued and prolonged global economic downturn".
The plants -in Belgium, France, Germany and Britain -were intended to come on stream over the next four years. Together, they would have produced a total of 2 million tonnes of fuel annually.
Ineos is the largest private company in Britain and was founded just over a decade ago. The company's rapid growth has been funded by debt financing, which it used to acquire more than 70 chemical-production sites across 14 countries.
The company says it is now cancelling all non-essential expenditure, and recently announced that it hoped to renegotiate the terms of loans totalling more than £5 billion (US$7.4 billion).
Stephen Hawking is taking a position in Canada.
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